Yatiri Bio Announces Licensing Option for AML Treatment
Yatiri Bio, Inc., a precision medicine company focused on biomarkers in oncology, announced on March 24, 2026, that it has entered into an exclusive global option to license agreement with Oscotec, Inc., for denfivontinib (SKI-G-801), a multikinase inhibitor targeted at Acute Myeloid Leukemia (AML), according to GlobeNewswire PE. Under the agreement, Yatiri Bio holds the exclusive option to license the drug for development and commercialization.
Details of the Agreement and Technology
Yatiri Bio’s ProteoCharts™ platform uses deep neural networks to integrate proteomic profiling with clinical data and functional testing in patient-derived models, according to the announcement. The company has identified a biomarker profile that signals high responsiveness to denfivontinib in AML patients, and this profile is FLT3-independent, allowing it to address a broader patient population than traditional therapies. This biomarker approach differentiates denfivontinib from other FLT3 inhibitors by targeting underserved patients in the current standard of care.
Development Strategy and Company Focus
Yatiri Bio is developing a Laboratory Developed Test (LDT) at its CLIA/CAP-accredited facility to stratify patients for denfivontinib clinical trials, which aims to ensure enrollment of responsive populations and accelerate the path to regulatory approval, as stated in the release. Pilgrim Jackson, CEO of Yatiri Bio, said, ‘This agreement exemplifies our strategy of using AI-driven proteomic intelligence to unlock hidden clinical value in oncology assets.’ Oscotec CEO Taeyoung Yoon added, ‘This collaboration with Yatiri Bio demonstrates Oscotec’s commitment to the unstoppable global trend in drug development: AI-based precision medicine.‘
Implications for Asset Optimization
The agreement represents a model for AI-enabled optimization of therapeutic assets, with Yatiri Bio combining the drug candidate and human data with its proteomic AI platform to execute a biomarker-driven strategy for de-risking regulatory approval, according to GlobeNewswire PE. As widely-known context, precision medicine in oncology often involves biomarker identification to improve treatment efficacy, though this deal specifically highlights Yatiri Bio’s focus on oncology biomarkers.
